Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The Michael J. Fox Foundation has expanded its trial platform to include patients with atypical parkinsonism, an umbrella term for various rare diseases.
Researchers have more than doubled the known number of brain regions using a mix of magnetic resonance imaging and data-derived algorithms.
GlaxoSmithKline has set up a rheumatoid arthritis clinical trial running on Apple’s ResearchKit framework.
Nostrum has spun out of a pair of Spanish research institutions with ambitions to use supercomputer-powered computational simulations to improve drug discovery.
The National Cancer Institute has joined with three top European research institutions to create a globally accessible repository of 1,000 cancer cell models.
Siemens Venture Capital has invested in Riffyn, a developer of R&D design software that is weeks away from introducing its first commercial product.
Bionext has picked up Rhenovia Pharma's cell signaling modeling technology and the R&D team that developed it to form a subsidiary, TheraScape.
Novartis has turned to Cure Forward's matchmaking tool for patients and trial recruiters for help identifying potential participants for its cancer…
Mount Sinai has reported a jump in enrollment in a Phase III trial of a Bayer drug after it used natural language processing to sift through EHRs.
Pfizer has signed up to use clinical trial technologies from Oracle, a company it has stuck with as its Big Pharma peers have defected to Medidata.